Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:BDRX News 10 December 2025

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2 This article looks at where BDRX stock stands on December 10, 2025, the latest clinical and regulatory news from Biodexa, the company’s increasingly complex capital structure, and how third‑party models and analysts are framing the risk–reward profile into 2026.
10 December 2025
··
Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Published: December 10, 2025 — U.S. pre‑market sessionAll data and news current as of early U.S. trading hours on Dec. 10, 2025. Fed Day Starts Quiet for Indexes, Wild for Individual Stocks Wall Street is waking up to a classic “calm on the surface, chaos underneath” kind of Fed day. S&P 500, Nasdaq 100, Dow Jones and Russell 2000 futures are only fractionally lower or higher in pre‑market trading, with moves generally within a few tenths of a percent as investors wait for the Federal Reserve’s final rate decision of 2025.Yahoo Finance+3StockAnalysis+3Morningstar+3 Markets widely expect another 25‑basis‑point cut, but the
10 December 2025
··········
Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

U.S. stock futures are edging higher early Wednesday as traders brace for the Federal Reserve’s final policy decision of 2025, with markets pricing in a high probability of another 25‑basis‑point rate cut. Futures on the Nasdaq 100, S&P 500 and Dow are modestly green, while the 10‑year U.S. Treasury yield hovers near 4.18% and commodities like silver trade at record highs above $61 an ounce. TipRanks+1 Beneath the calm surface of the indexes, however, the real fireworks are in pre‑market trading. A handful of thinly traded SPACs and micro‑cap biotechs are posting triple‑digit gains, joined by a distressed hotel REIT
10 December 2025
··········

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Go toTop